RE:RE:RE:RE:RE:Hard belly fatDidn't know they had space there. That's helpful. They've continued to say they are still refining TH-1904 with docerubicin in the lab. And we know they must be figuring out a TKI to add to it for hematologic cancers since they've added that into the presentation.
I believe the reference to the placebo was how in the general population, the weight loss and diet control that supervision provides has a positive placebo effect. They didn't face that in HIV patients. So getting that treatment "delta" is harder. For most of the trials there was positive liver fat reduction in both trial groups. It definitely was strong in the two Gilead trials and in Genfit's, which was the surprise one that did elafibranor in.
The most recent Phase 2 for NovoNordisk semaglutide showed a 17% placebo resolution of NASH on their definition. The highest dose of the drug was 40% though so it was statistically significant. Their problem is that 45% of the treatment group had nausea and it did nothing for any fibrosis readings. As we've seen with their other indications for weight lose, it does a pretty amazing job there and in the NASH test the treatment group lost 13% weight vs. 1% for placebo. It's a darn good weight lose drug.
Given that GHRH does fit in with the general MOA of being a "fat-buster" stimulating something that works the liver fat, you'd think it will eventually get added in to the lists since it's fairly close to the thyroid agonists or glucagen approach. I've found when I've talked to a few biotech analysts that they think growth hormone pretty immediately and all the nasty side effects around it from overuse. They've never heard of growth hormone releasing hormones which, as we know, is very different. It will likely take the trial and them doing every NASH conference they can with their data to get it in those lists. IT would certainly help if the analysts who follow NASH add it in to their database. You'd think once the trial is fully loaded up on clinicaltrials, some will notice it then.
jfm1330 wrote: Remember, they rent lab space at UQAM, the university where Dr. Beliveau is a professor. So they are already in a place where they have personnel to take care of the animal part of the whole research process, so if they need to hire a full time employee dedicated to that for them, it means that they are doing some intensive animal testing and they are planning to do that in the future. If early phase I is positive, they will have a lot of work because the combination of peptides, linkers and drugs are numerous.
SPCEO1 wrote: Now, I have to think the animal testing for TH-1902 is completed. So, one wonders what they migth be planning to test goign forward. We have no idea what they have been up to in the labs and what progress they may have been making on new versions of the drug (TH-1906 perhaps). But if they are committing to hiring someone like this, rather than farming it out to a consultant, that would seemingly indicate there may be more going on than we are presently aware of. Hopefully, they are coming up with some really interesting things as they work to understand more about PDC's.
jfm1330 wrote: On the french version of the career page they are looking to hire a laboratory animal technician dedicated to cancer research. To hire a ful time tech for that purpose means they are working intensively on animal testing. So maybe we will see more stuff on that front.